Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01435395 · ClinicalTrials.gov registry record · Phase 1
Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme
A Phase 1 study, sponsored by Emory University.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT01435395 is a Phase 1 study that has completed, run by Emory University. The registered enrollment target is 12 participants.
The verdict
NCT01435395, a Phase 1 study, has completed, sponsored by Emory University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring anti-epileptic medications will have to be at least 10 days off EIAEDs. Only non-EIAEDs are accepted.
Interventions
- DRUG Temozolomide, bevacizumab and bortezomib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2011-12 |
| Est. Completion | 2016-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01435395
The ClinicalTrials.gov registry entry for NCT01435395 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Emory University, which has 1,208 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Temozolomide, bevacizumab and bortezomib is the first listed.
NCT01435395 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01435395 about?
NCT01435395 is a clinical study titled "Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme". This is a single-center (Emory University), open-label, single arm, phase I study to assess safety and toxicity of bortezomib in combination with bevacizumab and escalating doses of temozolomide for patients with recurrent glioblastoma multiforme. Patients requiring anti-epileptic medications will h...
What is the current status of trial NCT01435395?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2011-12. Estimated completion is 2016-04.
What interventions are being tested in trial NCT01435395?
The interventions under investigation include: Temozolomide, bevacizumab and bortezomib (DRUG).
Who is sponsoring clinical trial NCT01435395?
This trial is sponsored by Emory University, which has 1,208 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.